MEPs Against Cancer
feb 2 2013.jpg
mac group picture.jpg
MEPs Against Cancer (MAC), a European Parliament Interest Group
MAC members of the of the Eighth Legislature 2014-2019:
Alojz Peterle, MAC President (EPP, Slovenia), Nessa Childers MAC Vice President (S&D, Ireland) Pavel Poc, MAC Vice President (S&D, Czech Republic) Charles Tannock MAC Vice President (ECR, UK), Ivo Belet (EPP, Belgium) Lynn Boylan (GUE/NGL, Ireland) Biljana Borzan (S&D, Croatia), Cristian Buşoi (EPP, Romania), Matt Carthy (GUE/NGL, Ireland), Deirdre Clune (EPP, Ireland), Therese Comodini Cachia (EPP, Malta), Miriam Dalli (S&D, Malta) Jose Inacio Faria (ALDE, Portugal) Lorenzo Fontana (NI, Italy), Lidia Joanna Geringer de Odenberg (S&D, Poland), Nathalie Griesbeck (ALDE, France) Theresa Griffin (S&D, UK) Françoise Grossetête, (EPP, France), Marian Harkin (ALDE, Ireland), Brian Hayes (EPP, Ireland), Anneli Jäätteenmäki (ALDE, Finland), Livia Járóka (HU, EPP), Karin Kadenbach (S&D, Austria), Sean Kelly (EPP, Ireland), Andrey Kovatchev (EPP, Buglaria), Miroslav Mikolášik (EPP, Slovakia), Piernicola Pedicini (EFDD, Italy) Sirpa Pietikäinen (EPP, Finland), Michèle Rivasi (Greens/EFA, France), Christel Schaldemose (S&D, Denmark), Maria Lidia Senra Rodriguez (GUE/NGL, Spain) Jutta Steinruck (S&D, Germany)Dubravka Šuica (EPP, Croatia), Tibor Szanyi (S&D, Hungary), Lieve Wierinck (ALDE, Belgium), Jana Žitňanská (SK, ECR)
"I think it is crucial for this term to provide more added value in the fight against cancer at the EU level, as well as better co-operation with stakeholders in the Member States. What is of the utmost importance is a concrete preventive policy in order to diminish the inflow of new cancer patients, which has been also the wish of the cancer patients in the EU."
- Mr Alojz Peterle, MAC President
The MEPs Against Cancer (MAC) group is an informal group of Members of the European Parliament (MEPs) at the European Parliament committed to actions against cancer. The MEPs Against Cancer work together in order to improve cancer prevention control and prevention in Europe, in the belief that European cooperation adds value to member state actions. In order to address the challenges faced by the EU, MAC works together with the European Commission and the Council, and collaborate with relevant organisations to reduce cancer incidence by 15% by the year 2020.
In the 2014 to 2019 legislature the strategic goal of the MEPs Against Cancer (MAC) group is to reduce cancer incidence by:
For more information on the working of the MAC group, please consult our strategic roadmap 2014-2019.
Interact with us
Like us on Facebook
Follow us on Twitter
See us on Flickr
Why we do what we do: The facts speak for themselves
Cancer is not one disease but over 200 different types of disease, ranging from the well-known big cancer killers to rarer conditions
In 2012, there was an estimated 3.4 million new cases (excluding non-melanoma skin), and 1.8 million cancer deaths in Europe.
Both genders were affected almost equally: of the 3,439,598 new cancer cases diagnosed in 2012, 53.2% were among men and 46.8% among women.
There were 1,754,550 cancer deaths, of which 55.9% were in men and 44.1% in women. The biggest killers of the 1.8 million deaths in 2012 were lung, colorectal, breast, and stomach cancers.
Although cancer survivorship figures have increased, survival rates differ vastly across Europe. Countries with lowest survival for most cancers (Bulgaria, Estonia, Latvia, Lithuania, Poland, and Slovakia) are in Eastern Europe. Here, survival is below the European mean, particularly for good prognosis cancers like colon, rectum, lymphomas, and skin melanoma. Nordic countries (with the exception of Denmark), central European countries such as Austria, Belgium, France, Germany, Switzerland, and Netherlands, and some countries in southern Europe (Italy, Portugal, and Spain), have the best survival for most cancers.
Childhood cancer remains a public health issue. Survival at 5 years from diagnosis for children (0-14 years) for all cancers combined is generally good, with 79% now surviving (2005–2007), up from 76% in 1999–2001.